Commercialization of Human Visceral Adipocytes

人内脏脂肪细胞的商业化

• 批准号: 6689059
• 负责人: YOLANDA Renee LEA-CURRIE
• 金额: $ 10万
• 依托单位: ZEN-BIO, INC.
• 依托单位国家: 美国
• 财政年份: 2003
• 资助国家: 美国
• 起止时间: 2003-09-01 至 2004-02-28
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/6689059
• 关键词: adipocytes; body composition; cell line; cell population study; cell sorting; clinical research; growth media; human tissue; method development; tissue /cell culture

DESCRIPTION (provided by applicant): The US is experiencing an epidemic rise in obesity [1] and related co-morbidities, such as type 2 diabetes. Epidemiological studies demonstrate that these co-morbidities are specifically correlated with visceral (intra-abdominal) fat deposition. To elucidate this association, an ideal model, human visceral adipocytes, must be made available to researchers. Zen-Bio, Inc. will address this need by developing a characterized, commercially accessible source of cultured human visceral preadipocytes. Preliminary data indicate that visceral preadipocytes are distinct from subcutaneous adipocytes, requiring individualized culturing techniques. Aim 1 of this proposal will seek to maximize visceral preadipocyte recovery from small solid tissue samples by improving mechanical and enzymatic dissolution of tissue and removal of contaminating cell types. Aim 2 will focus on expansion of the visceral preadipocytes to at least 20 million cells by developing growth factor cocktails and determining optimal seeding densities. Aim 3 will assess two parameters, advanced age of a donor or increased time post-mortem, for negative impact on total cell recovery, viability and/or growth characteristics. This Phase I SBIR concentrates on developing specialized techniques needed for culture of visceral preadipocytes. In Phase II we will focus on differentiating these cells into mature visceral adipocytes, followed by optimization of cell-based assays to effectively utilize these cells.

描述(由申请人提供)：美国正经历肥胖症[1]和相关并发症(如2型糖尿病)的流行上升。流行病学研究表明，这些并存疾病与内脏(腹内)脂肪沉积特别相关。为了阐明这种联系，必须向研究人员提供一个理想的模型--人类内脏脂肪细胞。Zen-Bio公司将通过开发一种具有特色的、商业上可获得的培养人类内脏前脂肪细胞的来源来满足这一需求。初步数据表明，内脏前脂肪细胞与皮下脂肪细胞不同，需要个性化的培养技术。这项提案的目标1将寻求通过改善组织的机械和酶溶解以及去除污染细胞类型来最大限度地从小的固体组织样本中恢复内脏前脂肪细胞。目标2将通过开发生长因子鸡尾酒和确定最佳种植密度，将内脏前脂肪细胞扩增到至少2000万个细胞。AIM 3将评估两个参数，捐赠者的高龄或死后时间延长，以确定对总细胞恢复、活力和/或生长特征的负面影响。这一阶段的SBIR专注于开发培养内脏前脂肪细胞所需的专门技术。在第二阶段，我们将专注于将这些细胞分化为成熟的内脏脂肪细胞，然后优化基于细胞的分析，以有效地利用这些细胞。